A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of PF-06372865 In Subjects With Chronic Low Back Pain Using Naproxen As Positive Control
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs CVL 865 (Primary) ; Naproxen
- Indications Back pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 01 Sep 2018 Status changed to discontinued due to trial futility as per results published in the Pain.
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.